176 related articles for article (PubMed ID: 18714567)
1. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
2. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
3. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
4. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain.
Castellsagué X; Rémy V; Puig-Tintoré LM; de la Cuesta RS; Gonzalez-Rojas N; Cohet C
J Low Genit Tract Dis; 2009 Jan; 13(1):38-45. PubMed ID: 19098605
[TBL] [Abstract][Full Text] [Related]
6. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
7. Management of precancerous cervical lesions in iran: a cost minimizing study.
Nahvijou A; Sari AA; Zendehdel K; Marnani AB
Asian Pac J Cancer Prev; 2014; 15(19):8209-13. PubMed ID: 25339007
[TBL] [Abstract][Full Text] [Related]
8. A decade has passed...the Pap smear and cervical cancer.
Linder J
Am J Clin Pathol; 1997 Nov; 108(5):492-8. PubMed ID: 9353086
[No Abstract] [Full Text] [Related]
9. Human papillomavirus testing in cervical cancer screening.
Castle PE; Cremer M
Obstet Gynecol Clin North Am; 2013 Jun; 40(2):377-90. PubMed ID: 23732037
[TBL] [Abstract][Full Text] [Related]
10. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of cervical cancer.
Ibeanu OA
Cancer Biol Ther; 2011 Feb; 11(3):295-306. PubMed ID: 21239888
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France.
de Rycke Y; Tubach F; Lafourcade A; Guillo S; Dalichampt M; Dahlab A; Bresse X; Uhart M; Bergeron C; Borne H; Cancalon C; Lajoinie A; Bénard S
PLoS One; 2020; 15(2):e0228660. PubMed ID: 32053648
[TBL] [Abstract][Full Text] [Related]
15. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany.
Sheriff SK; Petry KU; Ikenberg H; Crouse G; Mazonson PD; Santas CC
Eur J Health Econ; 2007 Jun; 8(2):153-60. PubMed ID: 17308921
[TBL] [Abstract][Full Text] [Related]
17. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
18. Management of women with mild and moderate cervical dyskaryosis.
Flannelly G; Anderson D; Kitchener HC; Mann EM; Campbell M; Fisher P; Walker F; Templeton AA
BMJ; 1994 May; 308(6941):1399-403. PubMed ID: 8019248
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.
Kulasingam SL; Rajan R; St Pierre Y; Atwood CV; Myers ER; Franco EL
BMC Med; 2009 Nov; 7():69. PubMed ID: 19900264
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
